Sumgen pulls in SG1827 Phase 1 completion date to March 2026, then March passes
Hangzhou Sumgen Biotech's dose-finding trial for SG1827 has moved its primary completion date three times, most recently to a date already in the past, with no posted safety or dose data.
Executive Summary
- A Phase 1 dose-finding study of SG1827 in advanced tumors has stopped recruiting with its enrollment target met, putting the focus on the safety and dosing data the study was designed to generate.
- The trial's completion date has moved repeatedly, most recently pulled forward to a date that has already passed without a public update, raising the question of whether the sponsor is on track to report.
- No safety, dose-limiting toxicity, or recommended dose data have posted, so the trial's core purpose, defining a tolerable dose for further development, remains untested in public view.
- SG1827's target and mechanism are not established in available records, so its place in the advanced tumor field can be assessed only by modality and phase, not by mechanistic differentiation.
The change
NCT06076291, an open-label Phase 1 study of SG1827 in adults with advanced tumors, is designed to determine the incidence of treatment-emergent adverse events and to identify a maximum tolerated dose, maximum administered dose, or recommended Phase 2 dose. On July 15, 2026, the registry record for the trial showed the primary completion date moved from June 30, 2026 to March 18, 2026, a pull-in of 104 days. That new date has already elapsed as of the current date, and no results have posted to ClinicalTrials.gov. NCT06076291+1An Open-label Study of SG1827 in Subjects With Advanced Solid TumorsNCT06076291An Open-label Study of SG1827 in Subjects With Advanced Solid TumorsJul 15, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
A history of shifting dates
This is the third change to the trial's primary completion date since its original target of December 28, 2024. The date first moved to April 30, 2025, then to June 30, 2026, and most recently to March 18, 2026, a cumulative reshuffling of the timeline across three separate revisions. The trial's status changed from Recruiting to Active, not recruiting on June 27, 2025, the same date as the second completion-date revision, indicating enrollment had closed by then. The trial's overall completion date, covering long-term follow-up beyond the primary endpoint, remains listed as December 31, 2026. NCT06076291An Open-label Study of SG1827 in Subjects With Advanced Solid TumorsNCT06076291
Enrollment and design
The trial's enrollment target has held flat at 122 patients throughout, with no increase or reduction recorded against that anticipated figure, a pattern consistent with a Phase 1 study that completed its planned enrollment rather than one that expanded or contracted its cohort. The study enrolls adults with ECOG performance status 0 or 1, at least one measurable lesion, and adequate organ function, drawn from fourth-line-or-later advanced tumor patients across sites in China. The design carries two primary endpoints, adverse-event incidence and dose-finding, plus five secondary endpoints spanning objective response rate, immunogenicity, cytokine pharmacodynamics, and pharmacokinetics. NCT06076291An Open-label Study of SG1827 in Subjects With Advanced Solid TumorsNCT06076291
Where SG1827 sits
SG1827's molecular target and mechanism of action are not established in available records, so its competitive position can be framed only by modality and clinical stage. The active advanced tumor field includes Phase 3 programs such as OncoC4's gotistobart and Merck's belzutifan, and earlier-stage entrants including Moderna's mRNA-4359 and MediLink Therapeutics' YL211, none of which share a target match with SG1827 given the unresolved mechanism data. Sumgen's Hangzhou-based portfolio otherwise runs four trials active but not recruiting, four recruiting, and one terminated, out of nine trials total, a track record with no other terminations on the SG1827 program itself.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.